Beneficial Effects of Colestipol-Niacin on Coronary Atherosclerosis: A 4-Year Follow-up

JAMA: The Journal of the American Medical Association

Volumn 264, Issue 23, 1990, Pages 3013-3017

  Cashin Hemphill, Linda ^a   Mack, Wendy J ^a   Pogoda, Janice M ^a   Sanmarco, Miguel E ^a   Azen, Stanley P ^a   Blankenhorn, David H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; COLESTIPOL; LIPOPROTEIN; NICOTINIC ACID;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIET; DRUG COMBINATION; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEINS; CHOLESTEROL; COLESTIPOL; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMAN; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGE; NIACIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025678697     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1990.03450230049028     Document Type: Article

References (12)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
2. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
3. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
4. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Controlled Clin Trials. 1987;8:354-387.
5. Koch GG, Landis JR, Freeman JL, Freeman DH, Lehnen RG. A general methodology for the analysis of experiments with repeated measurement of categorical data. Biometrics. 1987;33: 133-158.
6. SAS/STAT User’s Guide. 6.03 ed. Cary, NC: SAS Institute Inc; 1988.
7. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
8. Levy RI, Brensike JF, Epstein SE, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:325-337.
9. Artzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis: the Leiden Intervention Trial. N Engl J Med. 1985;312:805-811.
10. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med. 1988;148:36-69.
11. Barboriak J, Pintar K, Korns M. Atherosclerosis in aortocoronary vein grafts. Lancet. 1974; 2:621-627.
12. Bulkley B, Hutchins G. Accelerated ‘atherosclerosis’: a morphologic study of 97 saphenous vein coronary artery bypass grafts. Circulation. 1977; 55:163-169.